Raynaud F - Search Results

1

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days.

Benson C, White J, De Bono J, O'Donnell A, Raynaud F, Cruickshank C, McGrath H, Walton M, Workman P, Kaye S, Cassidy J, Gianella-Borradori A, Judson I, Twelves C. Benson C, et al. Among authors: raynaud f. Br J Cancer. 2007 Jan 15;96(1):29-37. doi: 10.1038/sj.bjc.6603509. Epub 2006 Dec 19. Br J Cancer. 2007. PMID: 17179992 Free PMC article. Clinical Trial.

2

Preclinical pharmacology of 1069C85, a novel tubulin binder.

Raynaud FI, Kelland LR, Walton MI, Judson IR. Raynaud FI, et al. Cancer Chemother Pharmacol. 1994;35(2):169-73. doi: 10.1007/BF00686642. Cancer Chemother Pharmacol. 1994. PMID: 7987996

3

High-performance liquid chromatographic assay for the measurement of the novel microtubule inhibitor 1069C85 in biological tissues and fluids.

Raynaud F, Walton M, Judson I. Raynaud F, et al. J Chromatogr. 1993 Dec 22;622(2):243-8. doi: 10.1016/0378-4347(93)80272-6. J Chromatogr. 1993. PMID: 8150872

4

Biotransformation of the platinum drug JM216 following oral administration to cancer patients.

Raynaud FI, Mistry P, Donaghue A, Poon GK, Kelland LR, Barnard CF, Murrer BA, Harrap KR. Raynaud FI, et al. Cancer Chemother Pharmacol. 1996;38(2):155-62. doi: 10.1007/s002800050464. Cancer Chemother Pharmacol. 1996. PMID: 8616906

5

Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels.

Raynaud FI, Odell DE, Kelland LR. Raynaud FI, et al. Br J Cancer. 1996 Aug;74(3):380-6. doi: 10.1038/bjc.1996.369. Br J Cancer. 1996. PMID: 8695352 Free PMC article.

6

Phase I trial and pharmacokinetics of the tubulin inhibitor 1069C85--a synthetic agent binding at the colchicine site designed to overcome multidrug resistance.

Judson I, Briasoulis E, Raynaud F, Hanwell J, Berry C, Lacey H. Judson I, et al. Among authors: raynaud f. Br J Cancer. 1997;75(4):608-13. doi: 10.1038/bjc.1997.107. Br J Cancer. 1997. PMID: 9052420 Free PMC article. Clinical Trial.

7

Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.

Raynaud FI, Orr RM, Goddard PM, Lacey HA, Lancashire H, Judson IR, Beck T, Bryan B, Cotter FE. Raynaud FI, et al. J Pharmacol Exp Ther. 1997 Apr;281(1):420-7. J Pharmacol Exp Ther. 1997. PMID: 9103525

8

Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer.

McKeage MJ, Raynaud F, Ward J, Berry C, O'Dell D, Kelland LR, Murrer B, Santabárabara P, Harrap KR, Judson IR. McKeage MJ, et al. Among authors: raynaud f. J Clin Oncol. 1997 Jul;15(7):2691-700. doi: 10.1200/JCO.1997.15.7.2691. J Clin Oncol. 1997. PMID: 9215842 Clinical Trial.

9

Phase I study of oral JM216 given twice daily.

Beale P, Raynaud F, Hanwell J, Berry C, Moore S, Odell D, Judson I. Beale P, et al. Among authors: raynaud f. Cancer Chemother Pharmacol. 1998;42(2):142-8. doi: 10.1007/s002800050797. Cancer Chemother Pharmacol. 1998. PMID: 9654114 Clinical Trial.

10

Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.

Kelland LR, Sharp SY, O'Neill CF, Raynaud FI, Beale PJ, Judson IR. Kelland LR, et al. Among authors: raynaud fi. J Inorg Biochem. 1999 Oct;77(1-2):111-5. J Inorg Biochem. 1999. PMID: 10626362 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

344 results

Search Page

Filters